Abstract
Dyslipidemia is regarded as one of risk factors related to cardiovascular disease and hepatosteatosis widely. Due to westernized diet habits and lifestyle changes, there is a high prevalence of those lipid-dysregulated diseases, i.e. fatty liver, hyperlipidemia, diabetes etc. However, the liver holds the lipid homeostasis so hepatoprotective nutraceuticals against high-fat diet (HFD) induced dyslipidemia may be potential for a public demand. This study demonstrated that OSM containing 10% polysaccharides and 0.25% adenosine can decrease (pOphiocordyceps sinensis mycelium (OSM) also decreased (p<0.05) serum low-density lipoprotein cholesterol (LDLC) levels and the atherosclerosis index (LDLC/high-density lipoprotein cholesterol (HDLC)) in HFD fed mice. Regarding the liver damage, OSM supplementation attenuated serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) values, and liver tumor necrosis factor-α (TNF-α) levels in HFD fed mice. Taken together, OSM showed an ameliorative effect of the hepatosteatosis development and lipid-dysregulated-related diseases in a HFD habit.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
